A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In the continuing efforts to understand the benefits and risks of in utero exposure to 17P this study is designed to evaluate differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by Hologic (Protocol number 17P-ES-003).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AMAG Pharmaceuticals, Inc.; Lumara Health, Inc.
• Collaborator: Registrat-Mapi
• Treatments: 11-hydroxyprogesterone; 17-alpha-hydroxy-progesterone caproate

Criteria

Inclusion Criteria:

• 1. Maternal enrollment which resulted in a live birth in the 17P Efficacy Trial: A Multi-center, Randomized, Double-blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery.

2. During their involvement in the above protocol, mothers must have received at least one dose of study drug (Safety population).

3. Children between 22 and 25 months of age adjusted for gestational age.

Exclusion Criteria:

• 1. There is no parent/legal guardian available to sign an informed consent. 2. Born to women who are unblinded to study group assignment.